Stockwinners Market Radar for September 14, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:10 EDT Cathie Wood's ARK Investment bought 332K shares of Roblox today

20:07 EDT Novonix achieves key milestones with synthetic graphite - The company states: "NOVONIX is pleased to provide an update on production from its proprietary, continuous induction Generation 3 Furnaces at its Riverside, Tennessee facility. The Company previously reported its high-performance battery grade synthetic graphite met specification targets from its Furnaces. Production campaigns have been ongoing to provide both operating data and economic insight on this breakthrough technology. In the most recent campaign, material was produced that met all specifications while also reaching the equipment design throughput targets. The Company will continue with production campaigns to collect more operational data and provide mass-production material for sampling to potential customers. The achievement of these milestones highlights the potential of the Company's continuous induction Furnace technology in meeting production targets at competitive cost while reaching our high-energy efficiency target with a near zero-emission process. The Company is updating the engineering for both the process equipment and Riverside facility with an increased production target of up to 20,000 tonnes per annum (tpa), compared to the initial target of 10,000 tpa. This updated throughput will support KORE Power and other prospective customers with whom the Company is in discussions about product qualification, production timelines and potential supply agreements. The Company expects engineering work to confirm this full facility re-design to be completed in the first quarter of 2024 which will support the continued deployment of additional mass production equipment for the start of commercial production for KORE Power in late 2024."

19:04 EDT Embraer announces $288M order from Air Peace for five new E175s - The company stated: "Nigeria based Air Peace, West Africa's largest airline, has placed a firm order for five Embraer E175 aircraft. This strategic decision marks a significant step forward and is in alignment with Air Peace's ongoing strategy of modernising its fleet. This acquisition is in line with Air Peace's determination to become the operator of the largest and youngest fleet of aircraft in Africa. It reinforces Air Peace's commitment to enhancing its domestic and regional network connectivity and paves the way for further regional expansion. Deliveries of the 88 seat aircraft start in 2024. The value of the order, at list price, is $288.3M. Already an operator of Embraer's newest and largest jet, the E195-E2, these smaller aircraft will complement the airlines' existing fleet, allowing Air Peace to dynamically match capacity to demand, protecting yields and route viability."

18:58 EDT Robinhood exec sells $877K in common stock - In a regulatory filing, Robinhood disclosed that its Chief Creative Officer Baiju Bhatt sold 80.7K shares of common stock on September 12th in a total transaction size of $877K.

18:47 EDT Learn CW Investment extends business combination period to October 13 - Learn CW Investment announced that it has deposited into the company's trust account an aggregate of $115,000 to further extend the period of time the company has to consummate its initial business combination by an additional one month, from the current deadline of September 13, 2023 to October 13, 2023. This is the sixth of up to six one-month extensions permitted under the company's governing documents.

18:40 EDT Samsara CEO Biswas sells 89,800 class A shares - In a regulatory filing, Samsara CEO Sanjit Biswas disclosed the sale of 89,800 class A common shares of the company on September 12 at a price of $30.4779 per share.

17:27 EDT Lockheed Martin awarded $151.36M Air Force contract - Lockheed Martin was awarded a not-to-exceed $151.36M fixed-price-incentive contract for Bulgaria F-16 Block 70 production. This contract provides for the production of eight F-16 Block 70 aircraft. Work is expected to be completed by September 30, 2027. This contract involves Foreign Military Sales to the Republic of Bulgaria. This contract was a sole-source acquisition. Foreign Military Sales funds in the amount $68.07M are being obligated at time of award. The Air Force Life Cycle Management Center is the contracting activity.

17:26 EDT Adobe sees Q4 tax rate 18.5% - Says Firefly has generated over 2B images. Says digital content creation and consumption are exploding. Says saw strong momentum across AEP and native apps with the total book of business surpassing $600M during Q3. Says continues to be excited about the pending Figma acquisition. Sees Q4 tax rate 18.5%. Comments and guidance taken from Q3 earnings conference call.

17:16 EDT Organon's JADA System reaches efficacy endpoint in published study - Organon announced that Obstetrics & Gynecology, the peer-reviewed journal of the American College of Obstetrics and Gynecology, published the results of the RUBY study which reached its primary effectiveness outcome of successfully treating abnormal postpartum uterine bleeding and postpartum hemorrhage - PPH - with the JADA System. JADA is an intrauterine vacuum-induced hemorrhage control device intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. JADA achieved treatment success in both the vaginal - 92.5% - and cesarean birth - 83.7% - groups, regardless of the cause of the abnormal postpartum uterine bleeding. When reviewing patient cases that received standard PPH interventions plus the JADA System, lower blood loss prior to device insertion was associated with lower severe maternal morbidity.

17:03 EDT Atlassian names Zeynep Ozdemir as CMO, Kevin Egan as CSO - Atlassian (TEAM) announced two additions to its executive leadership team with the appointment of Zeynep Ozdemir as its Chief Marketing Officer and the promotion of Kevin Egan to Chief Sales Officer. Ozdemir will join the company on October 2 and will be responsible for all marketing functions across Atlassian. She brings a depth of experience in product marketing and demand generation, most recently from Palo Alto Networks (PANW) where she oversaw the company's rapid expansion into multiple cybersecurity categories. Atlassian is also promoting Kevin Egan to Chief Sales Officer effective October 2. Kevin joined Atlassian in May 2021 as the Head of Global Enterprise Sales, bringing over 25 years of enterprise sales experience and leadership to the company. Prior to Atlassian, Kevin served as the Vice President of North American Sales at both Slack and Dropbox (DBX) and held various senior sales leadership positions during his 10-year tenure at Salesforce (CRM).

17:02 EDT Copa Holdings reports August passenger traffic rose 13.3% y/y - Copa Holdings, S.A. released preliminary passenger traffic statistics for August 2023. For the month of August 2023, Copa Holdings' capacity increased by 12.8%, while system-wide passenger traffic increased by 13.3%, compared to 2022. As a result, the system load factor for the month was 87.0%, 0.3 percentage points higher than August 2022.

17:00 EDT Vasta Platform announces up to $12.5M share repurchase program - Vasta Platform Limited announced that its Board of Directors has approved a share repurchase program, or the Repurchase Program. Under the Repurchase Program, Vasta may repurchase up to US$12.5 million in Class A common shares in the open market, based on prevailing market prices, or in privately negotiated transactions, over a period beginning on September 18, 2023, continuing until the earlier of the completion of the repurchase or September 30, 2024, depending upon market conditions. Vasta's Board of Directors will review the Repurchase Program periodically and may authorize adjustments to its terms and size or suspend or discontinue the Repurchase Program. Vasta expects to utilize its existing funds to fund repurchases made under the Repurchase Program.

16:41 EDT Jupiter Wellness to change name, symbol - Jupiter Wellness announced that effective September 15, the company has changed its name to Safety Shot, Inc. and at the open of market has changed its ticker symbol and will be trading as (SHOT). The company recently acquired Safety Shot which is going into production at facilities across the U.S. in preparation for its launch in the fourth quarter.

16:39 EDT Nucor falls 4% to $158.11 after Q3 EPS guidance misses estimates

16:35 EDT Lennar says 'market conditions remained constructive for new homebuilders' in Q3 - Stuart Miller, Executive Chairman and Co-CEO of Lennar, said, "Market conditions remained constructive for new homebuilders during our third quarter, as the Fed continued to use tighter money supply and higher interest rates as tools to battle inflation, while enabling continued economic growth. At the same time, short housing supply, absorbed by strong primary and pent-up demand, continued to define a strong sales environment. Homebuilders continued to use incentives, including buy-downs, to offset rising interest rates and tighter capital, which limit affordability. Our solid third quarter performance reflects strong strategic focus, and even as the month of August saw another uptick in interest rates, we were able to continue to drive sales pace." Miller continued, "Against this backdrop, our third quarter earnings were $1.1 billion, or $3.87 per diluted share, compared to $1.5 billion, or $5.03 per diluted share last year. Our average sales price per home delivered was $448,000 in the third quarter, compared to almost $500,000 last year, and our home deliveries were 18,559, up 8%, and our new orders were 19,666, up 37%, year over year. Our homebuilding gross margin in the third quarter was 24.4%, reflecting cost reductions, and with homebuilding S,G&A expenses of 7.0%, led to a 17.4% net margin." "While our operating performance remained strong, we continued to strengthen and fortify our balance sheet and our future. During the quarter, we repaid $475 million of debt and repurchased $366 million of our common stock ending the quarter with homebuilding debt to total capital of 11.5%, the lowest in our history, no borrowings on our $2.6 billion revolver and cash of $3.9 billion. With cash on hand exceeding our debt, and with overall liquidity of $6.5 billion, our balance sheet has never been in a stronger position." Jon Jaffe, Co-CEO and President of Lennar, said, "During the quarter, we continued the execution of our land light strategy. This was evidenced by our years supply of owned homesites improving to 1.5 years from 2.2 years and our controlled homesite percentage increasing to 73% from 69% year over year. Operationally, our cycle time during the quarter was down 32 days sequentially as the improving supply chain and labor market positively impacted our production times. Concurrently, the Lennar Machine continued to drive sales pace in concert with production. Accordingly, quarterly starts and sales pace were 4.9 homes and 5.2 homes per community, respectively, and we ended the third quarter with approximately 1,400 completed, unsold homes, about one home per community." Miller concluded, "As the Fed continues to focus on its goal of reducing inflation, we have remained vigilant and focused on our operating strategies. As we look ahead to our fourth quarter, we expect to deliver between 21,500 to 22,500 homes with a gross margin between 24.4% to 24.6%. We will continue to fortify our balance sheet with significant liquidity and operate from a position of strength, repurchasing stock and reducing debt, thus enabling us to continue to execute on our core strategies and outperform in periods of growth as well as uncertainty."

16:33 EDT Lennar sees Q4 new orders 16,200-17,200 - Sees Q4 deliveries 21,500-22,500; Average sales price consistent with Q3.

16:31 EDT Granite awarded $12.5M Caltrans project - Granite has been awarded a time and materials contract by the California Department of Transportation, or Caltrans. Granite will clear and repair multiple rock and mudslide areas to restore access through the Sequoia National Forest near Kings Canyon National Park. The project, funded by Caltrans, is expected to generate $12.5 million of work and will be included in Granite's third-quarter CAP.

16:31 EDT Land's End names Bernard McCracken CFO - Lands' End announced that Bernard McCracken, the company's interim CFO since January and chief accounting officer since April 2014, has been named CFO.

16:19 EDT ConocoPhillips announces long-term pact for European regas capacity - ConocoPhillips (COP) announced further progress on its global liquefied natural gas strategy, signing a commercial agreement to secure additional regasification capacity in Europe at the Gate LNG terminal in the Netherlands. This agreement further complements the company's foundational LNG resource positions in Qatar and Australia, offtake and equity in Sempra's (SRE) recently sanctioned Port Arthur LNG Phase 1 project on the U.S. Gulf Coast, regasification agreement at the German LNG Terminal announced last year, and the offtake agreements at Mexico Pacific's Saguaro LNG export facility on the west coast of Mexico announced last month. "Adding capacity at the Gate LNG terminal fits well with our efforts to deliver reliable, lower-carbon energy into Europe from highly competitive LNG supply," said Bill Bullock, executive vice president and chief financial officer of ConocoPhillips. "Expanding our LNG footprint with agreements like this further enhances a balanced, diversified, and attractive portfolio as we progress our global LNG strategy."

16:17 EDT Warner Media CEO joins Roblox board - Roblox (RBLX) "announced the appointment of Jason Kilar to the company's board of directors. Kilar is an accomplished entrepreneur and chief executive who has led media and entertainment companies for more than 15 years, including most recently serving as Chief Executive Officer of Warner Media (WBD)".

16:16 EDT Kennedy Wilson president Mary Ricks to retire - Kennedy Wilson announced Mary Ricks has decided to retire as President of Kennedy Wilson and as Director on the company's Board. Mary will serve as a consultant to Kennedy Wilson to aid in the transition. "As my trusted partner and dear friend, Mary has made a significant impact on me personally and has been instrumental in growing our company from an entrepreneurial start-up into a global real estate leader," said Kennedy Wilson Chairman and CEO William McMorrow. "I am grateful to have had the opportunity to work side-by-side with Mary over the last three decades. She is a fearless leader with a team-first attitude, and we will miss her greatly." Concurrently, former Executive Vice President Matt Windisch was promoted to President of Kennedy Wilson.

16:10 EDT NRx Pharmaceuticals announces agreement with LifeSci Associates - NRx Pharmaceuticals announced that it has entered into an agreement with LS Associates, a division of LifeSci Advisors, pursuant to which LSA will provide certain consulting services to the company, including but not limited to, arranging for the provision of the company's Interim CFO. In connection with the Agreement, the company appointed Richard Narido to serve as Interim CFO of the company. As Interim CFO, Narido will serve as the company's principal financial officer and principal accounting officer.

16:09 EDT Rockwell Automation, Infinitum announces exclusive agreement - Rockwell Automation and Infinitum announced an exclusive agreement to jointly develop and distribute a new class of high-efficiency, integrated low voltage drive and motor technology. This solution will significantly save energy and cut costs for industrial customers globally, while helping them reduce their carbon footprint and become more sustainable. As companies grow more energy conscious and look to reduce greenhouse gas emissions, variable frequency drives with high-efficiency motors have increasingly come into focus. According to the International Energy Agency, electric motors consume approximately 40% of the electricity consumed globally, with the percentage rising to nearly 70% for industrial companies. Under this agreement, Rockwell's market-leading PowerFlex drive technology will be combined with Infinitum's high-efficiency Aircore EC motor system. This powerful package will help companies reduce their carbon footprint with a motor system that is 50% smaller and lighter, uses 66% less copper, and consumes 10% less energy than traditional iron core motors.

16:08 EDT J.B. Hunt to acquire brokerage assets of BNSF Logistics - J.B. Hunt Transport Services announced J.B. Hunt's subsidiary, J.B. Hunt Transport, Inc., has entered into a definitive agreement to purchase the brokerage operations of BNSF Logistics, LLC. BNSF Logistics, LLC is an affiliate of BNSF Railway, providing third-party logistics services for the movement of full truckload, flatbed, temp-controlled, drayage, expedited, and less-than-truckload services to a large and diverse group of customers through both an employee and agent model. BNSF Logistics also provides warehouse, retail specialty, heavy-haul and project services, which are not included in the transaction. "As we continue to work with BNSF Railway to develop solutions that drive value for customers, we recognized a unique opportunity to combine the companies' efforts to serve the transportation market with 3PL services and leverage the investments J.B. Hunt has made in our technology platform, J.B. Hunt 360 degrees ," said John Roberts, CEO of J.B. Hunt. "This acquisition is another step forward in our mission to create the most efficient transportation network in North America."

16:06 EDT Prime Impact Acquisition I trading halted, news pending

16:02 EDT Primerica names Tracy Tan as successor to CFO - Primerica "announced the appointment of Tracy Tan to the role of Executive Vice President, Finance reporting to the company's Chief Executive Officer, Glenn Williams beginning on October 16, 2023. Tan will assume the role of Chief Financial Officer as of the date that the Company's existing Chief Financial Officer relinquishes that title, which shall occur no later than April 1, 2024."

15:39 EDT Jin Medical International Ltd trading resumes

15:00 EDT General Motors says 20% wage increase over life of deal offered to UAW - General Motors stated in an update posted to its site that the company "submitted a record economic proposal to the UAW," including a 20% wage increase over the life of the agreement, with a 10% increase in Year 1. The company shared an employee letter from GM Chair and CEO Mary Barra, which states in part: "We continue to bargain in good faith, but with our contract set to expire at 11:59 p.m., I want to make sure you are completely informed... We are working with urgency and have proposed yet another increasingly strong offer with the goal of reaching an agreement tonight. Remember: we had a strike in 2019 and nobody won." Reference Link

14:12 EDT Harleysville Financial approves 5% stock repurchase program - Harleysville Financial announced that the board of directors has approved the commencement of a new stock repurchase program of up to 183,000 shares or approximately 5% of the company's outstanding shares of common stock. The repurchase program will commence immediately following the completion of the company's current repurchase program, which has approximately 53,795 shares remaining for repurchase. The repurchased shares will be held as treasury stock and will be available for general corporate purposes. Brendan McGill, President and CEO, stated, "The company's strategy is to maintain a strong balance sheet, practice sound capital management and build long-term value for our shareholders."

13:16 EDT L'Oreal announces appointments, new Deputy CEO in Charge of Divisions - China - L'Oreal announced a number of moves within its Executive Committee due to take place in Q1 2024, in addition to the creation of the new role of Deputy CEO in Charge of Divisions - L'Oreal China. Fabrice Megarbane will be appointed Chief Global Growth Officer, he will succeed Frederic Roze, who has announced his intention to retire at the beginning of next year, after 38 years with the company. As Chief Global Growth Officer, Megarbane will be in charge of accelerating growth, leading transformation projects and animating the Group's Zones. Megarbane will retain his current responsibilities until the end of January 2024. Vincent Boinay will be appointed President of the North Asia Zone and Chief Executive Officer of L'Oreal China. He will succeed Fabrice Megarbane, following his appointment as Chief Global Growth Officer. Boinay will move to Shanghai in the near future and will fully assume his new responsibilities at the beginning of February 2024. In light of the increased complexity of the Chinese market, Laurence Ma, currently General Manager of L'Oreal Luxe China, will be appointed to the newly created role of Deputy Chief Executive Officer in Charge of Divisions - L'Oreal China. Ma will continue to manage L'Oreal Luxe China, and will lead the other three Divisions. Ma's appointment will become effective at the beginning of February 2024. Emmanuel Goulin will be appointed President of Travel Retail and will join the Group's Executive Committee. He will succeed Vincent Boinay. Goulin's appointment will become effective at the beginning of 2024.

12:51 EDT Abbott tells The Fly physicians can continue to use Proclaim, Infinity systems - After the FDA posted a recall notice yesterday related to Abbott's implantable pulse generator that's used with the company's Proclaim and Infinity systems, a company spokesman issued the following additional background in a statement issued to The Fly: "Abbott has received reports indicating the loss of Bluetooth connectivity between Abbott's implantable Proclaim and Infinity systems and its paired patient controller after a patient has undergone an MRI. Based on these occurrences, Abbott previously updated the patient controller Instructions for Use - IFU - and patient controller application MRI-mode screen on smartphones reminding the patient to not delete the paired Bluetooth connection between their Implantable Pulse Generator - IPG - and the patient controller. Abbott has distributed a physician communication to reinforce the importance of following the steps regarding MRI scans outlined in the IFU. The company has communicated this action to physicians and regulatory bodies. No products need to be returned to the company or replaced. Importantly, physicians can continue to use the Proclaim and Infinity systems."

12:14 EDT AT&T committed to reaching 200M people with 5G+ on mid-band by YE23 - Pascal Desroches, CFO at AT&T, spoke at the Bank of America Media, Communications & Entertainment Conference where he provided an update to shareholders. Desroches made the following key points: Over the past three years, AT&T has repositioned around its strengths in 5G and fiber. Desroches stated that AT&T is benefitting from the continued and consistent execution of this strategy. Desroches also noted that continued higher postpaid average revenues per user and healthy wireless service revenue growth reflect the health of the company's wireless operations. Desroches reiterated that he's confident in the company's full-year free cash flow guidance of better than $16 billion. Additionally, Desroches stated the company expects third-quarter free cash flow in the $4.5-5.0 billion range. As previously indicated, the primary factors supporting the company's cash outlook are full-year 2023 adjusted EBITDA growth of 3+ percent, largely in-line capital investment and lower handset payments for full-year 2023 compared to 2022. AT&T expects to deliver continued profitable 5G and fiber customers in the third quarter. In wireless, Desroches said he expects to add postpaid phone customers to the base in the third quarter thanks to the company's disciplined and sustainable go-to-market strategy even with the market experiencing continued normalizing in demand trends. AT&T remains committed to: Reaching 200 million people with 5G+ on mid-band spectrum by year-end 2023. Passing 30+ million consumer and business customer locations with fiber by the end of 2025.

12:00 EDT CS Disco falls -10.1% - CS Disco is down -10.1%, or -79c to $6.96.

12:00 EDT Sunlands Online falls -14.3% - Sunlands Online is down -14.3%, or -80c to $4.83.

12:00 EDT Trinseo rises 15.6% - Trinseo is up 15.6%, or $1.23 to $9.13.

11:56 EDT Google says Chromebooks to get 10 years of automatic updates - Alphabet's Google announced new ways to keep Chromebooks up and running even longer. All Chromebook platforms will get regular automatic updates for 10 years - more than any other operating system commits to today. "We're also working with partners to build Chromebooks with more post-consumer recycled materials (PCR), and rolling out new, power-efficient features and quicker processes to repair them," the company said. "And at the end of their usefulness, we continue to help schools, businesses and everyday users find the right recycling option." Starting in 2024, if users have Chromebooks that were released from 2021 onwards, they'll automatically get 10 years of updates. For Chromebooks released before 2021 and already in use, users and IT admins will have the option to extend automatic updates to 10 years from the platform's release after they receive their last automatic update. Google is also rolling out updates that help make repairs even faster, with new repair flows allowing authorized repair centers and school technicians to repair Chromebooks without a physical USB key. Reference Link

11:07 EDT GE sees tracking to high end of Q3 EPS, free cash flow guidance

10:32 EDT Vicinity Motor reports C$1.9M order for four buses - Vicinity Motor announced the receipt of a new purchase order from Simcoe County in Ontario, Canada for four Vicinity Classic buses valued at over C$1.9M, marking its 7th re-order from Vicinity. Per the terms of the supply agreement, Simcoe County has ordered four of the company's 35-foot Clean-Diesel Vicinity Classic buses for delivery in 2024.

10:19 EDT Moderna says CHMP adopts positive opinion on updated Covid-19 vaccine - Moderna announced that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has adopted a positive opinion recommending marketing authorization for Spikevax, its updated COVID-19 vaccine containing spike proteins for the XBB.1.5 sublineage of SARS-CoV-2 for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older. Following the CHMP's positive opinion, the European Commission will make an authorization decision on the use of Moderna's updated COVID-19 vaccine for autumn/winter 2023, the company stated.

10:13 EDT Stratasys says 'nothing new' in 3D Systems' September 13 announcement - Stratasys (SSYS) issued the following statement in response to a press release issued by 3D Systems (DDD) on September 13: "The proposal referenced in 3D Systems' press release on September 13 did not revise the terms, or change any substantial details, of the revised proposal made by 3D Systems on September 6. The Stratasys Board of Directors previously reviewed 3D Systems' September 6 revised proposal and unanimously determined that the revised proposal, which is 35% lower than the value implied by 3D Systems' July 13 proposal and comprises consideration with a nominal value of only $15.26 per Stratasys ordinary share as of September 11, 2023, continues to significantly undervalue Stratasys and does not constitute a "Superior Proposal" as defined in Stratasys' merger agreement with Desktop Metal (DM). The merger agreement filed by 3D Systems on September 13 is in substantially the same form as it shared with the Stratasys Board on September 6, as 3D Systems itself admits. The Stratasys Board's response to 3D Systems' September 6 revised proposal remains unchanged."

10:05 EDT SharpLink says SaharaBets first U.S. sports betting operator using 'C4 BetSense' - SharpLink Gaming announced that SaharaBets will be the first U.S. sports betting operator to begin integration of SharpLink's "innovative new 'C4 BetSense' technology into its online betting platform." SharpLink and SaharaBets will commence testing "C4 BetSense" beginning with the 2023/2024 NFL season and running through March Madness in 2024. "We believe there is a very big lift possible for sportsbook operators with 'C4 BetSense' integration, helping to convert a much greater number of sports fans into sports bettors and yielding a material increase in betting handle due to smarter bet recommendations and 'call to action' offers that distinctly resonate with and motivate each individual player to place wagers. In fact, early analysis of our prototype system indicates the potential lift could be as high as 20% -- and perhaps even higher," said Rob Phythian, Co-Founder and CEO of SharpLink.

10:01 EDT TradeUP Acquisition Corp trading resumes

10:00 EDT TriMas asset relocation completed ahead of schedule - TriMas announced that its TriMas Packaging group has successfully completed, ahead of schedule, the previously announced relocation of certain production assets from a California manufacturing facility to other facilities in Indiana and Arkansas. As a result, TriMas Packaging will be exiting a 160,000 sq. ft. leased facility in Rohnert Park, California, by the end of 2023. Additionally, TriMas Packaging has now completed the insourcing of a substantial portion of activities at third-party warehouse and distribution centers in New Jersey and Nevada to capture logistics savings.

10:00 EDT Genius Sports falls -10.6% - Genius Sports is down -10.6%, or -64c to $5.40.

10:00 EDT International Game rises 9.1% - International Game is up 9.1%, or $2.73 to $32.79.

10:00 EDT Mytheresa rises 15.9% - Mytheresa is up 15.9%, or 59c to $4.34.

09:56 EDT TradeUP Acquisition Corp trading halted, volatility trading pause

09:47 EDT Genius Sports falls -10.6% - Genius Sports is down -10.6%, or -64c to $5.40.

09:47 EDT AMC Entertainment rises 9.1% - AMC Entertainment is up 9.1%, or 75c to $8.99.

09:47 EDT International Game rises 9.4% - International Game is up 9.4%, or $2.82 to $32.88.

09:41 EDT CF Industries, POSCO evaluating joint U.S.-based clean ammonia project - CF Industries Holdings and POSCO Holdings announced that the companies are evaluating a joint venture to construct a low-carbon clean ammonia plant at CF Industries' Blue Point Complex in Ascension Parish, Louisiana, United States, along with long-term low-carbon clean ammonia offtake into South Korea. As part of their evaluation, CF Industries and POSCO will initiate a front-end engineering and design study on autothermal reforming ammonia production technology. Should the project move forward, POSCO expects to import low-carbon clean ammonia from the facility to South Korea to support decarbonization of POSCO's own and third-party coal-based power generation facilities. Additionally, POSCO intends to convert low-carbon clean ammonia into hydrogen in order to use low-carbon hydrogen in gas-based power plants and in the steel-making process itself. The FEED study is expected to be completed in the second half of 2024, with a final investment decision by CF Industries and POSCO to follow.

09:27 EDT Caesars reports 'suspicious activity' in IT network from cyberattack - In a regulatory filing, Caesars says it recently identified suspicious activity in its information technology network resulting from a social engineering attack on an outsourced IT support vendor used by the company. "Our customer-facing operations, including our physical properties and our online and mobile gaming applications, have not been impacted by this incident and continue without disruption. After detecting the suspicious activity, we quickly activated our incident response protocols and implemented a series of containment and remediation measures to reinforce the security of our information technology network. We also launched an investigation, engaged leading cybersecurity firms to assist, and notified law enforcement and state gaming regulators. As a result of our investigation, on September 7, 2023, we determined that the unauthorized actor acquired a copy of, among other data, our loyalty program database, which includes driver's license numbers and/or social security numbers for a significant number of members in the database. We are still investigating the extent of any additional personal or otherwise sensitive information contained in the files acquired by the unauthorized actor. We have no evidence to date that any member passwords/PINs, bank account information, or payment card information were acquired by the unauthorized actor. We have taken steps to ensure that the stolen data is deleted by the unauthorized actor, although we cannot guarantee this result. We are monitoring the web and have not seen any evidence that the data has been further shared, published, or otherwise misused... While no company can ever eliminate the risk of a cyberattack, we believe we have taken appropriate steps, working with industry-leading third-party IT advisors, to harden our systems to protect against future incidents. These efforts are ongoing. We have also taken steps to ensure that the specific outsourced IT support vendor involved in this matter has implemented corrective measures to protect against future attacks that could pose a threat to our systems."

09:08 EDT Vontier partners with Chevron on iNFX solution - Vontier (VNT) and Invenco by GVR, a subsidiary of Vontier announced they have partnered with Chevron Products, a division of Chevron (CVX), to deploy their cloud-based microservices platform, iNFX at Chevron and Texaco gas stations in the U.S. The iNFX Electronic Payment Server is a cloud managed, fit-for-purpose IoT based microservices platform that provides a better customer experience through faster payment transactions, simple integration with other devices at the site, greater uptime, and the ability to bring new capabilities & features to market faster.

09:06 EDT Mayo Clinic, GE HealthCare enter strategic healthcare collaboration - Mayo Clinic and GE HealthCare announce a strategic healthcare collaboration for research and product development programs aimed to transform the experience of patients and clinicians in the practice of radiology and the delivery of novel therapies. The Strategic Collaboration for Innovation in Medical Imaging and Theranostics comprises Mayo Clinic and GE HealthCare scientists, technology developers, clinicians and other healthcare providers. The collaboration seeks to better equip clinicians with technology to precisely diagnose and treat medical conditions and personalize the patient experience at each step of their care journey through the clinical translation of novel technologies and approaches to medical imaging and theranostics.

09:05 EDT Scilex announces completion of its SP-103 Phase 2 trial - Scilex Holding, a majority-owned subsidiary of Sorrento Therapeutics, announced the completion of its SP-103 Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy in subjects with acute LBP. Objectives of the trial were to assess safety and tolerability of SP-103 and to provide treatment effect estimates in patient population that can be used to power future studies. The trial enrolled 75 subjects, 38 received SP-103, and 37 received placebo. Topical systems were applied to the area of most tenderness in the lower back in 12-hours ON/ 12-hours OFF regimen. Preliminary analysis demonstrated the following results: No Serious Adverse Events or deaths observed. No Treatment Emergent Adverse Events leading to early withdrawal. None of the subjects in the active group and 3 subjects in placebo group had AEs of special interest. Incidence of dermal AEs or application site reactions was low overall. SP-103 was safe and well-tolerated. Increase in lidocaine load in topical system by three times, compared with approved ZTLido, 5.4% vs. 1.8%, did not result in signs of systemic toxicity or increased application site reactions with daily applications over one month treatment. A meaningful reduction of pain over the first week, using SPID-7 analysis, -1.5 (95% CI: -0.2 to 3.2) was observed in sub-population of patients with higher severity of muscle spasms. Overall, the trial achieved its objectives. Scilex continues to analyze the data to gather a full understanding of the analgesic signal, population to be selected for subsequent trial, and specific indication to be pursued for product registration. The Company is very encouraged to see reduction of pain as compared to placebo in patients whose LBP is driven predominantly by muscle spasms. Scilex is also very pleased with the safety outcome of the trial, confirming our expectations and performance of SP-103 previously demonstrated in phase 1 trials.

09:03 EDT Natera announces new study as part of I-SPY 2 trial - Natera announced a new study as part of the I-SPY 2 trial, sponsored and operated by Quantum Leap Healthcare Collaborative, that will use Signatera, Natera's personalized and tumor-informed molecular residual disease, or MRD, test, to monitor response to neoadjuvant therapy in breast cancer patients across all subtypes. This prospective study, in which 600 patients will be monitored in real time, will support efforts to establish circulating tumor DNA, or ctDNA, as a composite endpoint and generate additional data on post-surgical ctDNA status in patients treated with neoadjuvant therapy. It expands on the existing collaboration with the ISPY-2 consortium that has led to the publication of multiple studies validating the use of Signatera for neoadjuvant response monitoring and predicting recurrence risk, including studies published in Cancer Cell1 and Annals of Oncology.

09:03 EDT Ibex, Genesys partner to deliver omnichannel AI-enabled customer experience - ibex announced a partnership with Genesys, a global cloud leader in AI-powered experience orchestration, to offer next-generation omnichannel customer experience and contact center solutions. This collaboration will enable both companies to enhance and expand their CX and contact center offerings. "We are delighted to partner with Genesys to offer the most comprehensive range of next-generation CX solutions to our growing roster of blue chip and digital-first clients," said Jim Ferrato, Chief Information Officer, ibex. "Leveraging Genesys Cloud CX as part of our enterprise services will allow ibex to drive greater automation, which will improve our employee experience and create unified interfaces for all channels and solutions. It will also offer enhanced flexibility and customization options to tailor solutions to meet specific enterprise needs."

09:02 EDT Nano Dimension to vote 'AGAINST' Stratasys' merger with Desktop Metal - Nano Dimension (NNDM) announced that it opposes and intends to vote against Stratasys (SSYS) proposed merger with Desktop Metal Inc. (DM) and urges fellow Stratasys shareholders to join in casting votes against the transaction at the company's Extraordinary General Meeting of Shareholders to be held on September 28, 2023. Nano Dimension is Stratasys' largest shareholder and owns approximately 14.1% of Stratasys' outstanding ordinary shares. Yoav Stern, CEO of Nano Dimension, commented, "The opportunity to vote on Stratasys' proposed merger with Desktop Metal is quickly approaching. We express to our fellow Stratasys shareholders our deep conviction that this merger would be highly dilutive and result in significant value destruction, sacrificing profitability and financial flexibility of Stratasys for limited upside. We intend to vote AGAINST the proposed merger. Abstaining or not voting is not enough to show your opposition and we urge our fellow Stratasys shareholders to join us in voting AGAINST the transaction." Nano Dimension's opposition to a merger of Stratasys with Desktop Metal is based on the following rationale:

09:00 EDT Altamira Therapeutics reports efficacy outcome from Bentrio clinical trial - Altamira Therapeutics announced further positive and statistically significant efficacy data from the randomized controlled NASAR clinical trial, which evaluated their Bentrio nasal spray in seasonal allergic rhinitis. Bentrio nasal spray is formulated as a drug-free and preservative-free gel emulsion designed to help protect against airborne allergens such as pollen or house dust mites. The NASAR trial enrolled 100 SAR patients in Australia who were randomized at a 1:1 ratio to receive either Bentrio or saline nasal spray, the current standard of care in drug-free SAR management. Study participants self-administered the treatment for two weeks three times per day, or as needed. As previously reported, the NASAR trial met its primary efficacy endpoint, with the Bentrio group showing a mean rTNSS over the treatment period of 5.0 points vs. 6.1 points for the saline spray group, resulting in a statistically significant difference of 1.1 points in the ANCOVA model1 in favor of Bentrio. Additional data, which have become subsequently available from the NASAR trial, confirm and reinforce the body of evidence demonstrating Bentrio's efficacy in SAR management. The mean instantaneous TNSS, which measures nasal symptoms 'at the moment' and served as a secondary efficacy endpoint, was 4.4 points and 4.8 points at baseline. At the end of the treatment period, it reached 2.9 points in the Bentrio group vs. 3.7 points in the placebo group. Like for the TNSS, the difference of 0.8 points in the ANCOVA model was significantly larger for the Bentrio group . The treatment effect in favor of Bentrio became apparent from the first day of the two-week treatment period and was observed across the four nasal symptoms covered by the TNSS. It was particularly pronounced in patients with moderate to severe symptom levels. Importantly, the alleviation of symptoms was associated with an improvement in health-related quality of life, as measured by the Rhinoconjunctivitis Quality of Life Questionnaire. The RQLQ has been designed to collect information on functional problems caused by allergic rhinitis. At baseline, the mean total RQLQ score was 3.0 points in the Bentrio group and 2.8 points in the saline spray group and decreased to 1.7 points and 2.4 points, respectively, by Day 14. The improvement in the Bentrio group was significantly superior for each of the 8 RQLQ items, including nasal symptoms, eye symptoms, non-nose/eye symptoms, activity limitations, sleep problems, practical problems and emotional function. Further, the read-out from the NASAR trial suggest that Bentrio helps reduce the need for relief medication. Whereas a similar share of patients required relief medication during the treatment-free run-in period, more participants in the Bentrio group could abstain from relief medication during the treatment period, but only 4 out of 15 in the saline spray group.

08:48 EDT Hepion announces results from translational study on rencofilstat - Hepion Pharmaceutical announced positive results from a translational research study in which Hepion's lead drug candidate, rencofilstat, was administered to diseased human lung tissue from patients with idiopathic pulmonary fibrosis, IPF. In this study, FibroFind obtained diseased lung tissue from two individuals undergoing lung transplantation for end-stage IPF, a deadly fibrotic lung disease. Precision cut lung slices were made and individually incubated in culture with rencofilstat, nintedanib, pirfenidone, or combinations of the compounds for four days. Proteomics analyses were conducted on lung tissues at the end of treatment by PhenoSwitch Bioscience and identified 1,953 unique proteins in the samples. These analyses demonstrated: Rencofilstat monotherapy altered levels of between 8 and 28% of the 1,953 proteins identified in PCLuS depending on dose and donor. This represented changes 2 - 4-times greater than nintedanib or pirfenidone in PCLuS from the first donor, and 2-fold greater than nintedanib in the second donor; Rencofilstat, in combination with nintedanib, altered levels of 16 - 42% of the 1,953 proteins depending on donor, which represented 2.7 - 7.8-fold more than nintedanib alone; Rencofilstat, in combination with pirfenidone, altered levels of 12 - 46% of the 1,953 proteins depending on donor, which represented 1.3 - 2.2-fold more proteins altered by pirfenidone alone; Among three studies reporting differentially expressed proteins in IPF lungs compared to normal controls,1-3 up to 41% of the reported differential proteins were also found in the current PCLuS study to be altered by rencofilstat alone or in combination. Furthermore, the majority of rencofilstat's effects on the overlapping proteins were opposite to the disturbances reported in the large IPF studies, which is consistent with disease-normalizing actions of rencofilstat; The normalizing actions of rencofilstat monotherapy and combinations spanned many important classes of proteins, including multiple isoforms of collagens, laminins, integrins, keratins, and MHC antigens. Additional, notable proteins whose abundance was positively shifted by rencofilstat included TIMP3, nidogen, surfactant protein C, cathepsin B, myeloperoxidase, lysozyme, mimecan, and asporin; and Cyclophilin B protein, a primary target of rencofilstat, was reported to be elevated in IPF lung tissue,1,2 suggesting a pathogenic role, and rencofilstat alone and in combination in PCLuS decreased tissue levels of cyclophilin B.

08:46 EDT ReShape receives NIH SBIR grant for bloc-stim neuromodulation device - ReShape Lifesciences announced that the Company was awarded a $331,541 Small Business Innovation Research, SBIR, grant for the development of ReShape's Diabetes Bloc-Stim Neuromodulation device, which utilizes its proprietary vagus nerve block technology platform, combined with vagus nerve stimulation, for the treatment of Type 2 diabetes, a prominent disorder associated with obesity. Specifically, the grant will fund the exploration of high-resolution endoscopic ultrasound probes to aid accurate placement of the electrodes laparoscopically on the celiac and hepatic branches in large animals. "Awarding this third NIH SBIR grant brings the total received awards to $900,000, and is a testament to both our non-dilutive funding strategy and the NIH's strong interest in the development of the novel DBSN device and its potential to address the significant, global diabetes market," stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. "With the funding, to date, our team has successfully completed the pre-clinical development of the device, which utilizes bioelectronics to adjust insulin production and manage blood glucose to potentially treat Type 2 diabetes and hypoglycemia. It has also shown that this innovative technology may reduce diabetics' dependence on medications in a very individualized manner with the goal of reducing costs of treatment and complications that arise from poorly controlled blood glucose and non-compliance with diabetes medications."

08:44 EDT Tingo Group launches next generation of TingoPay Super App - Tingo Group announced the launch of the next-generation version of its super app, TingoPay. Darren Mercer, Chief Executive Officer of Tingo Group, Inc. commented: "Having recently completed the beta-test program, I am delighted to be launching the full version of our TingoPay super app and to expand its market reach through the addition of an iOS version alongside the next-generation Android version. I am also thrilled to be deepening our relationship with global payment provider, Visa, as they continue to power our range of retail-customer payment services and digital wallet alongside our wide range of merchant services. I believe that TingoPay's expanded range of features, value-added services and billing partners makes us one of the most comprehensive super-apps in the fast-growing African market and I am confident we will further strengthen our market-position, increase our brand awareness, and attract significant numbers of users through our ambitious rolling program of technological development and product enhancements."

08:43 EDT Alpha Tau treats first patient with inoperable pancreatic cancer - Alpha Tau Medical announced that a patient with advanced inoperable pancreatic cancer has been treated in a clinical trial at Hadassah Medical Center in Jerusalem, Israel. The trial is designed for a broad range of solid tumor patients who do not qualify for participation in other existing trials or who do not have other treatment options according to the treating physician. "We are dedicated to improving the lives and giving hope to cancer patients and their families, and we believe that Alpha DaRT has the potential to transform the treatment landscape for malignant tumors worldwide," said Alpha Tau CEO Uzi Sofer. "Treating this patient with advanced inoperable pancreatic cancer, who may not have had other life-saving options at this stage, is very encouraging as we continue to execute on our unwavering mission to reach those patients with high unmet need. We are pursuing our objective of establishing Alpha DaRT as a treatment option for this terrible illness with our ongoing studies of pancreatic cancer in Israel and Montreal."

08:41 EDT Vita Coco announces partnership with Becky G - The Vita Coco Company announces a partnership with award-winning singer, songwriter, actress and activist Becky G. As the new face of the brand, Becky G, a fierce "advocate for authenticity," perfectly aligns with Vita Coco's brand values. "From our first conversations, it was clear that Becky G was going to be an amazing ambassador and partner for Vita Coco," said Mike Kirban, co-founder and executive chairman of The Vita Coco Company. "Not only is she someone who is unapologetically herself, she does so while embracing her roots and championing her community - a community that increasingly mirrors the diverse and growing family of Vita Coco drinkers."

08:41 EDT Urban-Gro signs multiple contracts with clients for aggregate value of over $2M - urban-gro announced that the Company signed more than $2M of contracts spread across existing clients in target sectors including industrial, aerospace, laboratories, and hospitality. Collectively, the contracts include architecture and design, engineering, and construction management services for clients in the Midwest and Southern United States. The Company anticipates that the revenue for these projects will be predominantly recognized over the next two quarters. Additionally, and not contemplated in the aforementioned contract value, urban-gro signed a master service agreement to provide engineering services for two national hotel chains in the United States. Bradley Nattrass, Chairman and CEO, commented, "We remain focused on expanding our presence in our target sectors and these contracts demonstrate the continued execution of our diversification strategy as well as our team's technical capabilities and multi-sector expertise that are highly valued in today's marketplace."

08:35 EDT TTEC Holdings awarded federal contract to improve contact center operations - TTEC Holdings subsidiary TTEC Government Solutions was awarded a contract to modernize the customer experience at a wide range of federal agencies with the U.S. General Services Administration, or GSA. Through TTEC Digital, the company will provide consulting and advisory services for federal agencies supported by GSA. Partner agencies will receive tailored guidance, support, and recommendations. TTEC Digital provides capabilities in Generative AI, Chatbots, and Voicebots, and applies AI for advancements in Training, Knowledge Management, Talent Acquisition, and Retention, to provide journeys that are on par with customer experiences in commercial markets. The contract is valued at more than $4M and includes a 12-month base period with two, 12-month options.

08:33 EDT Neurocrine's NDA for Ingrezza granules accepted by FDA - Neurocrine announced the FDA has accepted its New Drug Application - NDA - for Ingrezza oral granules, a new sprinkle formulation of Ingrezza capsules for oral administration. The agency set a Prescription Drug User Fee Act target action date of April 30, 2024. The Ingrezza oral granules capsules are intended to be opened for sprinkling on soft foods prior to administration. The NDA filing included chemistry, manufacturing, and controls information and data demonstrating the bioequivalence and tolerability of the Ingrezza oral granule sprinkle capsules compared to the currently approved Ingrezza capsules. Ingrezza is currently available as the only one-capsule, once-daily treatment option with no complex titration for adults with tardive dyskinesia and the treatment of chorea associated with Huntington's disease.

08:28 EDT Kaival Brands announces bulk order for BIDI Sticks from H.T. Hackney - Kaival Brands Innovations Group announced that it has shipped a bulk order of BIDI Sticks to H.T. Hackney, one of the largest wholesale distributors in the United States. The order is valued at more than $750,000 and was shipped in the fourth quarter of fiscal year 2023. H.T. Hackney had not ordered more than $100,000 of BIDI Stick product in a single order since March 2023. Eric Mosser, Chief Executive Officer & President of Kaival Brands, said, "This bulk order represents the resumption of activity with one of our key distribution partners and is an important step towards accelerating our product sales. Hackney is a long-term, dedicated distributor that recognizes the important business value of only distributing compliant and legitimate, non-illicit ENDS products and shares our commitment to championing youth-access prevention. Given recent enforcement efforts by the FDA to address the problem of illicit and illegal vaping products, we are optimistic that this bulk order is an indication of a positive trajectory in revenue growth."

08:09 EDT Lytus Technologies launches Lytus Studios - Lytus Technologies announces the set up and launch of LYTUS STUDIOS in the USA for its content creation and technology services that will serve global markets. LYTUS STUDIOS plans to offer cutting edge creative services along with specialized technology infrastructure for film, video, series, commercials, events, corporate and digital industries. LYTUS STUDIOS will combine next age technology that will bring together VR, AR, MR into a composite XR for film & video entertainment. LYTUS STUDIOS is also building a unique video streaming service, LYTUS PLAY. This service will initially be offered to Lytus Technologies' current million + users in India while launching the service concurrently in the USA. Lytus Technologies CEO Dharmesh Pandya said, "We are very keen to expand technology services that are transformative. With LYTUS STUDIOS we will be able to enhance the entertainment experience of our global customers by creating curated content for our upcoming platforms and for the global entertainment world."

08:07 EDT GXO Logistics acquires PFSweb for $7.50 per share - GXO Logistics announced they have entered into a definitive agreement pursuant to which GXO will acquire PFSweb for $7.50 per share in cash, representing an equity value of approximately $181 million. The enterprise value is $142 million and includes PFSweb's cash balance of $39 million at June 30, 2023. GXO CEO Malcolm Wilson said, "PFS is an ideal acquisition for GXO: it enhances our exposure to new high-growth verticals in North America and adds important capabilities to our offerings. Over the past 25 years, the PFS team has established a successful track record in both direct to consumer and B2B channels, and they've built a rock-solid reputation with many of the world's most iconic brands by deploying an order fulfillment platform that rivals the largest enterprise 3PL providers in the industry. We're excited to bring them on board and look forward to driving additional shareholder value through disciplined capital allocation and continued investment in high growth opportunities." Terms of the Transaction: The merger agreement provides for GXO, through a subsidiary, to commence a tender offer to acquire all outstanding shares of PFSweb at an all-cash price of $7.50 per share of PFSweb common stock. The closing of the tender offer will be subject to certain conditions, including the tender of at least a majority of the outstanding shares of PFSweb common stock, the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. Upon the successful completion of the tender offer, GXO will acquire all shares not acquired in the tender through a second-step merger. The transaction is expected to close in the fourth quarter of 2023.

08:05 EDT Landos Biopharma announces strategic research collaboration with KU Leuven - Landos Biopharma announced a strategic research collaboration to investigate the effects of NX-13 on epithelial cells with the Inflammatory Bowel Disease Team at KU Leuven and University Hospitals Leuven, a leading European research university and hospital network known for its innovation in Leuven, Belgium. The NEXUS Phase 2 proof-of-concept clinical trial of NX-13 in patients with moderate-to-severe ulcerative colitis was initiated during the second quarter of 2023. Recruitment, screening and randomization of patients continues, with top-line results on track for the fourth quarter of 2024. The results are expected to provide further insight into the impact of NX-13 on gene expression and regulation, and cytokine responses. "We are thrilled to collaborate with Dr. Verstockt and the IBD Team at KU Leuven, an established global research center at the leading edge of clinical and translational research," commented Dr. Fabio Cataldi, Executive Vice-President & Chief Medical Officer at Landos. "We expect this research will broaden our already strong data foundation for the novel and unique bimodal mechanism of action of NX-13 and further validate the role of immunometabolism in inflammation and IBD."

08:04 EDT Nemaura Medical provides update on Nasdaq compliance status, process - Nemaura Medical provided an update regarding the status of its compliance with Nasdaq continued listed standards and anticipated next steps to maintain its listing on The Nasdaq Capital Market. The Company currently does not expect to regain compliance with the above-referenced Nasdaq listing criteria prior to the expiration of the applicable grace periods and, as such, anticipates receipt of a delisting determination from the Staff promptly following the expiration of the grace periods. Importantly, however, upon receipt of such determination, the Company may request a hearing before a Nasdaq Hearings Panel to address the listing deficiencies, which request will stay any suspension or delisting action by Nasdaq at least until a hearing is held and any extension that may be granted by the Panel to the Company following the hearing has expired. In that regard, pursuant to the Nasdaq Listing Rules, the Panel has the discretion to grant the Company an additional extension period not to exceed 180 calendar days from the date of the forthcoming delist determination. The Company plans to timely request such hearing and is considering all options available to it to regain compliance and maintain its listing on The Nasdaq Capital Market.

08:02 EDT Worksport advances towards launch of SOLIS Solar Cover - Worksport announces significant strides in the development of its groundbreaking COR battery system, designed to complement the launch of the SOLIS solar cover. This cutting-edge duo is poised to empower remote power supply and extend the driving range of electric pickup trucks, thereby underscoring Worksport's commitment to sustainability and innovation as a cleantech company. "We recognize the importance of safety and user experience. By integrating advanced technology with user-centric designs, we're ensuring that our COR battery system is not just innovative but also robust and intuitive," stated Steven Rossi, CEO of Worksport. "Our end goal is to offer our customers a system that's tailored to their unique needs - from the scorching heat of Arizona to the cold fronts of Alaska."

07:59 EDT Draganfly secures first defense orders for its Commander 3XL with U.S. military - Draganfly announces that it has secured its first defense orders for its Commander 3 XL with the U.S. Military. The Commander 3 XL is being utilized to enhance mission success by enabling confident and accurate navigation through unfamiliar terrain and GPS denied environments. "We are thrilled that the U.S. Military has seen fit to utilize the Commander 3 XL platform to aid in achieving their mission objectives in unfamiliar terrain and GPS denied environments," said Cameron Chell, President and CEO of Draganfly. "We are excited by the expanding opportunities to collaborate and deliver solutions meeting evolving needs and challenges in the defense space."

07:42 EDT RH director sells $7.76M in common stock - In a regulatory filing, RH disclosed that its director Carlos Alberini sold 25K shares of common stock on September 12th in a total transaction size of $7.76M.

07:37 EDT Shyft Group releases 2023 sustainability report - The Shyft Group published its 2023 sustainability report, Charging Towards a Sustainable Future, highlighting the company's sustainability activities, performance and results from calendar year 2022. "In collaboration with our Board of Directors, the dedicated team spearheading our sustainability efforts, and each individual within the Shyft community, we are forging ahead with a unified purpose and unwavering commitment," said Josh Sherbin, Chief Legal and Compliance Officer. "Our accomplishments in 2022 reflect our continued commitment to a future that's brighter and more sustainable for all."

07:32 EDT Almaden Minerals obtains provisional injunction related to decision of Economia - Almaden Minerals reports that the Mexican Federal Administrative Court has granted a provisional injunction to Almaden's Mexican subsidiary, Minera Gorrion, relating to the submission issued by Mexico's Ministry of the Economy, Economia, to the district court which is overseeing the implementation of the February 2022 decision of Mexico's Supreme Court requiring indigenous consultations prior to the granting of mineral titles to the Ixtaca project. Economia's submission to the District Court was made in February 2023 and aims to deny the two mineral title applications to the Ixtaca project which were first made by Almaden in 2002 and 2008, and which in turn led to the grant of mineral titles in 2003 and 2009, respectively. As previously reported, these mineral titles were reduced to application status as a result of the February 2022 decision of the SCJN. Duane Poliquin, Chair of Almaden, stated, "We filed this complaint with the Federal Administrative Court back in March and despite the long delay we are encouraged that we may finally have the opportunity to explain why we believe the Economia Submission is a seriously flawed document."

07:31 EDT Nauticus Robotics announces offshore service agreement with Shell - Nauticus Robotics (KITT) announced its entry into a service contract with Shell (SHEL). The initial scope of work includes inspection services on a Shell subsea field development in the Gulf of Mexico, and the contract contemplates visible future inspection service projects. The contract follows Nauticus' successful qualification phase for autonomous methods of subsea operations for inspection services. The new contract acknowledges Nauticus' successful transition to a fully operational offshore services provider. "I am incredibly pleased with the progress the team has made in our collaboration with Shell and to embark on this new project with one of the world's leading energy companies," said Nicolaus Radford, CEO of Nauticus. "Nauticus now has visibility long term IMR services work for Shell and the opportunity to become the preferred supplier for this advanced work. We recognize the significance of this opportunity with Shell and look forward to the execution of this project work."

07:12 EDT Mobileye, FAW Group announce new strategic partnership - FAW Group, one of the largest Chinese automotive groups, and Mobileye have announced a new strategic partnership leveraging their respective industry advantages in software, hardware and technology products. The two sides will work together to create new products based on Mobileye SuperVision and Mobileye Chauffeur platforms, to empower customers with safe, enjoyable driving experiences. More details about the projects will be shared in the months ahead.

07:10 EDT Visa to engage with stockholders on exchange offer program - In a regulatory filing last night, Visa announced that it is engaging with its common stockholders on the subject of potential amendments to its Seventh Restated Certificate of Incorporation that would authorize Visa to conduct an exchange offer program that would have the effect of releasing transfer restrictions on portions of Visa's Class B common stock in "a manner that is designed to be economically equivalent to existing arrangements with respect to Class A and Class C common stockholders' exposure to certain litigation." Visa stated: "Visa's board of directors has reviewed, and has authorized management to engage with its common stockholders regarding, these potential Certificate of Incorporation amendments. If ultimately proposed, the amendments would become effective only if approved by a majority of the outstanding shares of Class A, Class B and Class C common stock, each voting as a separate class."

07:09 EDT SkyWater Technology announces John Sakamoto as chief operating officer - SkyWater Technology announced that John Sakamoto will be joining the company as president and chief operating officer, effective September 25. In his new role, Sakamoto will be responsible for all day-to-day business and manufacturing operations. Reporting to CEO Thomas Sonderman, Sakamoto will join SkyWater with 25 years of experience in various executive leadership positions.

07:07 EDT Vincerx Pharma doses first patient in Phase 1 trial evaluating VIP943 - Vincerx Pharma reported that the first patient has been dosed in the Phase 1 trial evaluating VIP943 in patients with relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia. "Dosing of the first patient is a major achievement for the VIP943 development program and our next-generation bioconjugation platform. This achievement occurred 17 business days from receiving our safe to proceed letter, underscoring the enthusiasm from our investigators and the strong execution capabilities of the Vincerx team," said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx. "VIP943 is the first ADC candidate from our pioneering bioconjugation platform, designed to address the challenges of current ADCs, by increasing the therapeutic index. We are the first company to bring to the clinic a legumain-cleavable linker and the first to utilize a kinesin spindle protein inhibitor as an ADC payload. This innovative and proprietary combination has generated strong preclinical evidence of activity and safety and has the potential to shift the treatment paradigm for patients with CD123+ hematologic malignancies. We look forward to evaluating the potential of VIP943 and expect to report preliminary safety and pharmacology data from our Phase 1 study in 2024."

07:06 EDT FitLife Brands announces approval to list common stock on Nasdaq market - FitLife Brands announced that the Company has received approval to list its common stock on the Nasdaq Capital Market. Trading on Nasdaq is expected to commence on Monday, September 18, 2023. Dayton Judd, the Company's Chairman and CEO, commented, "We are excited for the opportunity to list our shares on Nasdaq. We hope that this action will enhance the visibility of the Company in the capital markets and improve the trading volume of our stock."

07:03 EDT Biohaven completes enrollment in Phase 3 study of taldefgrobep alfa - Biohaven announced completing enrollment in RESILIENT, the Phase 3 pivotal study of taldefgrobep alfa in spinal muscular atrophy. Biohaven targeted randomizing approximately 180 patients in this global trial conducted in 9 countries. The primary objective is to determine the safety and efficacy of taldefgrobep alfa compared to placebo after 48 weeks of subcutaneous administration as determined by change from baseline in the 32 item Motor Function Measure total score.

07:03 EDT Aris Mining begins trading on NYSE American as 'ARMN', leaves OTCQX - Aris Mining's common shares will commence trading on the NYSE American at market open today under the ticker symbol ARMN. Aris Mining's common shares will continue trading on the TSX under the ticker symbol ARIS. Concurrent with the start of trading on the NYSE American, Aris Mining's common shares will cease trading on the OTCQX market. Shareholders are not required to take any action. Aris Mining's share purchase warrants and notes will not trade on NYSE American.

07:02 EDT Tilray's Montauk Brewing expands distribution beyond Northeast - Montauk Brewing, a subsidiary of Tilray Brands, announced the beginning of a highly-anticipated expansion beyond the Northeast that will begin in Georgia, and continue to other major markets in the U.S. later this year. "This is a huge moment for Montauk Brewing, as we begin a sustainable path to becoming a national brand. Since Montauk Brewing was founded 11 years ago, the buzz around its innovative, easy-drinking beers has spread far beyond New York. Consumers and retailers across the country constantly ask us when Montauk will be available in their cities, and we're excited that we can now show them why Montauk is the top craft brewer in New York," said Ty Gilmore, President of U.S. Beer at Tilray.

07:01 EDT Cyngn secures four new patents for AI-powered autonomous vehicle technologies - Cyngn announced the issuance of four new patents granted by the United States Patent and Trademark Office for its autonomous vehicle technologies. In August, the company announced the procurement of four additional patents as a result of their proprietary technology for vehicle sensors, obstacle detection systems, autonomous driving predictions and multi-channel object matching. The publication of four additional patents brings the company's total US patents to 14, further solidifying its position as a pioneer and leader in the autonomous industrial sector.

07:00 EDT Laser Photonics receives order from Navistar for MarkStar Laser Marking System - Laser Photonics received an order for its MarkStar laser system for laser marking from Navistar, a company in the transport sector. Navistar will utilize the piece of machinery to mark numerous materials, including aluminum, alloy and rolled steel.

06:57 EDT Aecom selected as Lead Designer for I-35 expansion project in Texas - Aecom has been appointed as Lead Designer for the Lone Star Constructors joint venture, which has been selected by the Texas Department of Transportation to manage the design, delivery, and maintenance of the I-35 Northeast Expansion South Project in Bexar County, Texas. The project consists of four miles of non-tolled improvements along I-35 from I-410 South to I-410 North. Aecom will design and deliver three elevated express lanes along I-35 in each direction, consisting of two elevated general purpose lanes and one HOV lane.

06:49 EDT Transocean granted $486M contract for Deepwater Aquila drillship in Brazil - Transocean announced a three-year award for the newbuild ultra-deepwater drillship Deepwater Aquila with a national oil company for work offshore Brazil. The contract is expected to commence in Q3 2024 and represents approximately $486M in firm backlog, excluding a mobilization fee of approximately 90 times the contract dayrate. Transocean has also agreed to acquire the outstanding interests in Liquila Ventures, a company formed to acquire the Deepwater Aquila, from its joint venture partners, Perestroika and Lime Rock Partners. Following this acquisition, Transocean will own and operate eight of the twelve ultra-deepwater, 1,400 short-ton hookload drillships in the world. The Deepwater Aquila is expected to be delivered from the shipyard in October 2023. Transocean is exploring various debt financing alternatives to partially fund the costs associated with acquiring the rig from the shipyard and preparing it for its contract in Brazil.

06:47 EDT Spire Global selected by Estuaire to monitor and reduce aviation missions - Spire Global was selected by Estuaire, a data firm empowering the aviation industry to reduce its environmental impact, to supply global aviation insights. Spire will provide its aircraft positional data, as well as its Flight Report, which aggregates hundreds of millions of daily satellite and terrestrial ADS-B positions into a one-row-per-flight information enriched with flight and aircraft data, for post-flight analytics and reporting needs. Estuaire monitors and analyzes aviation emissions including CO2, non-CO2 and aircraft lifecycle effects. The Estuaire suite of web applications supports airlines, lessors and aviation lenders in measuring and reducing their environmental impact.

06:07 EDT Bionomics provides update on Merck collaboration - Bionomics (BNOX) announced an update on the company's alpha7 Nicotinic Acetylcholine Receptor Positive Allosteric Modulator collaboration with Merck (MRK). Data for MK-4334, a novel clinical candidate developed by MSD and derived from Bionomics' original alpha7 nAChR PAM candidate, was recently presented at the Society for Chemical Industry and Royal Society of Chemistry 22nd Medicinal Chemistry Symposium, held in Cambridge, UK, September 10-13. Bionomics has a long-standing collaboration with MSD to identify novel alpha7 nAChR PAMs suitable for the treatment of cognitive disorders that address the limitations seen with nAChR agonists. MSD has subsequently developed MK-4334, a novel clinical candidate, which in early preclinical studies has shown improved drug like and pharmacological properties relative to BNC375. Under the 2014 exclusive Research Collaboration and License Agreement, MSD funds all research and clinical development, and worldwide commercialization of any resulting products. This collaboration generated payments of $20M upfront and $10M for a Phase 1 milestone. Bionomics is eligible to receive up to $465M in additional milestone payments for certain development and commercial milestones plus royalties on net sales of licensed drugs.

06:02 EDT New Relic announces completion of "go-shop" period - New Relic announced the completion of the 45-day "go-shop" period pursuant to the terms of the previously announced definitive agreement to be acquired by Francisco Partners, a global investment firm that specializes in partnering with technology businesses, and TPG, a leading global alternative asset management firm, for $87.00 per share in cash, representing an equity valuation of approximately $6.5B. The "go-shop" period concluded at 11:59 p.m. Pacific time on September 13, 2023. During the "go-shop" period, at the discretion of the company's Board of Directors, New Relic and representatives of Qatalyst Partners, financial advisor to the company, actively solicited alternative acquisition proposals from 53 potentially interested strategic and financial parties. None of the 53 parties contacted by New Relic submitted a competing acquisition proposal during the "go-shop" period. The Transaction is expected to close in late 2023 or early 2024, subject to the satisfaction of customary closing conditions and certain regulatory items, including the approval of New Relic's shareholders and customary merger control clearances. The waiting period for the Transaction under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 expired at 11:59 p.m. Eastern time on September 11, 2023. The Transaction is not subject to a financing condition. Upon completion of the Transaction, New Relic common stock will no longer be listed on any public market.

05:22 EDT AstraZeneca enters 15-year partnership with Future Biogas - AstraZeneca has agreed a 15-year partnership with Future Biogas to establish the UK's first unsubsidized industrial-scale supply of biomethane gas, and is investing in major energy efficiencies in its operations, totaling a commitment of GBP 100M. Energy from the biomethane facility will supply AstraZeneca's sites in Macclesfield, Cambridge, Luton and Speke with 100 gigawatt hours, or GWh, per year, equivalent to the heat demands of over 8,000 homes. Once operational in early 2025, the partnership will reduce emissions by an estimated 20,000 tons CO2 equivalent, adding renewable energy capacity to the national gas grid. The anaerobic digestion facility and long-term partnership with Future Biogas provide a blueprint for the commercial adoption of renewable gas in the UK. A competitive biomethane market can play a key role in the transition to net zero.

05:15 EDT Volvo to purchase near zero emission steel from H2 Green - Volvo's collaboration with H2 Green Steel for near zero emission steel is another step forward on the continued journey towards a net zero GHG emission value chain by 2040. Under the long-term agreement Volvo Group will purchase near zero emission steel from H2 Green Steel's new plant in Boden in Northern Sweden. Start of production is planned for end of 2025 with deliveries to Volvo Group starting mid-2026.